Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856544 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
A Phase 3 study of Arthritis, Rheumatoid, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 795
- Enrollment target
- 20
- Study locations
NCT00856544: Completed Phase 3 study of Arthritis, Rheumatoid, sponsored by Pfizer.
NCT00856544 is a Phase 3 study of Arthritis, Rheumatoid that has completed, run by Pfizer. The registered enrollment target is 795 participants, above the 612-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00856544, a Phase 3 study of Arthritis, Rheumatoid, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 795 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.
Primary Outcome
ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count (TJC); \>= 20% improvement in swollen joint count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP). For comparison of CP-
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CP-690,550
Study Locations (20)
Florida
- Pfizer Investigational Site - New Port Richey
- Pfizer Investigational Site - Ocala
- Pfizer Investigational Site - Plantation
- Pfizer Investigational Site - Port Richey
- Pfizer Investigational Site - Tamarac
- Pfizer Investigational Site - Tampa
Connecticut
- Pfizer Investigational Site - Danbury
- Pfizer Investigational Site - Hamden
- Pfizer Investigational Site - Trumbull
Illinois
- Pfizer Investigational Site - Maywood
- Pfizer Investigational Site - Oakbrook Terrace
- Pfizer Investigational Site - Rockford
California
- Pfizer Investigational Site - Palo Alto
- Pfizer Investigational Site - Stanford
Colorado
- Pfizer Investigational Site - Boulder
- Pfizer Investigational Site - Denver
Georgia
- Pfizer Investigational Site - Decatur
- Pfizer Investigational Site - Marietta
Alabama
- Pfizer Investigational Site - Huntsville
Arkansas
- Pfizer Investigational Site - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 795 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
What the finished NCT00856544 record still lists
NCT00856544 is an interventional study that assigns participants to a tested intervention. The registered 795 participants enrollment target is mid-sized for trials with a published cap, above the 612-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (30% higher).
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00856544 names 20 study sites across 8 states, led by Florida, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT00856544 about?
NCT00856544 is a clinical study titled "A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications". This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP...
What is the current status of trial NCT00856544?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2009-05. Estimated completion is 2011-01.
What conditions does trial NCT00856544 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT00856544?
The interventions under investigation include: Placebo (DRUG), CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT00856544?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00856544 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00856544's enrollment target sits among peer trials
795 6th of 27 higher than 22 of 27 other Arthritis, Rheumatoid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Rheumatoid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
-
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia